Teens and young adults should get new vaccines to prevent potentially deadly meningitis B infections, but only as an individual decision, not a routine recommendation, a federal panel decided Wednesday.
Teens and young adults should get new vaccines to prevent potentially deadly meningitis B infections, but only through individual decisions, not routine recommendations, a federal panel of experts decided Wednesday.
The 14-1 vote by the Advisory Committee on Immunization Practices (ACIP) falls short of the broad recommendation urged by parents whose children died from the disease and victims left disfigured or disabled. They said they feared the limited advisory will curtail wide access to the lifesaving shots.
“I field calls from parents all over this country who can’t get their hands on this vaccine,” Alicia Stillman, a Michigan mother whose 19-year-old daughter, Emily Stillman, died in 2013 from a fast-moving meningitis B infection, told the committee. “In 2015, we’ll become a community of haves and have-nots.”
But the ACIP panel, which advises the Centers for Disease Control and Prevention, agreed that historically low levels of the disease, limited data about the lasting effectiveness of the vaccines and potentially high costs didn’t warrant the wider recommendation.
Most Read Local Stories
- WA Senate candidate Tiffany Smiley criticizes Seattle Times, Starbucks, Seahawks
- Birders flock to 520 bridge to catch glimpse of rare visitor
- Inside the 'Northgate miracle,' which wasn't a miracle at all
- Bolt Creek fire was 'human-caused'; smoke drifts over Seattle again
- Pedestrian hit, killed near shooting scene in U District
Panel members approved a recommendation that says teens, along with their doctors and families, can get meningitis B vaccines between ages 16 and 23. They declined to approve a recommendation for wide use, but group members said the vaccines could appear on a list of shots relied on by doctors and parents.
Carl Buher, a 26-year-old Seattle man who lost three fingers and both legs below the knee to a meningitis B infection as a teen, called the lesser decision “disappointing.”
But he and others affected by the disease will continue to advocate for wider use, he said.
“We’ll keep working until we get it to that higher level of recommendation,” he said.
There are about 50 to 60 cases of meningitis B in adolescents and young adults in the U.S. each year, including between five and 10 deaths, data show. Between 1 million and 3 million people would need to be vaccinated to prevent a single death, scientists said Wednesday.
Vaccines are already routinely recommended for college-age students to prevent four other strains of meningitis, but not strain B.
Bacterial meningitis is a rare infection that attacks the linings of the brain and spinal cord. It’s typically spread by close contact through respiratory secretions, and older teens and young adults are particularly at risk.
The decision follows recent outbreaks of meningitis B infections on college campuses, including Princeton University, the University of California, Santa Barbara and, this year, the University of Oregon, where seven people have been infected and a student died.
Under the new recommendation, two newly licensed meningitis vaccines — Trumenba from Pfizer and Bexsero, now offered by GlaxoSmithKline — will be offered under “permissive” guidelines. That means the shots can be covered by private insurance and the federal Vaccines for Children program.
The ruling could affect vaccination recommendations at colleges and universities in Washington state. Although state schools don’t require any meningitis vaccinations, they recommend the four-strain vaccines, particularly for students who live in dorms or other on-campus housing.